Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech Reaches 50% Enrollment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP
Details : The company's primary product candidate, WST11 (padeliporfin), is undergoing evaluation in a pivotal Phase 3 clinical trial with patients for treating low-grade upper tract urothelial carcinoma.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : EIC Accelerator
Deal Size : $14.6 million
Deal Type : Funding
ImPact Biotech Receives €13.5M Investment from European Innovation Council
Details : The funds will used to advance the company-lead product WST11 (padeliporfin). Currently, it is being evaluated in late-stage clinical trials for treating low-grade upper tract urothelial cancer.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
July 24, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : EIC Accelerator
Deal Size : $14.6 million
Deal Type : Funding
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Presents Phase 3 Results from ENLIGHTED Study of Padeliporfin in Urothelial Cancer
Details : WST11 (padeliporfin VTP) is a vascular targeted photodynamic therapy which is a minimally invasive oncology platform, it is being investigated for Low Grade Upper Tract Urothelial Cancer.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 05, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP
Details : The company's primary product candidate, WST11 (padeliporfin), is presently undergoing evaluation in a pivotal Phase 3 clinical trial with patients for low-grade upper tract urothelial carcinoma.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech Presents Interim Data on Padeliporfin VTP in Urothelial Cancer
Details : The company's primary product candidate, WST11 (padeliporfin), is undergoing evaluation in a pivotal Phase 3 clinical trial with patients for treating low-grade upper tract urothelial carcinoma.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer
Details : ImPact Biotech is developing padeliporfin vascular targeted photodynamic (VTP) therapy, which is currently being evaluated for the treatment of patients with peripheral lung cancer.
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer
Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of solid tumors and Pancreatic Cancer and has received Fast Track designation and Orphan Drug Designation for adult patients with low-gr...
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 07, 2023
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of peripheral lung cancer and pancreatic cancer and has received Fast Track designation and Orphan Drug Designation for adult patients w...
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 08, 2023
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ENLIGHTED study aims to recruit 100 patients with low-grade UTUC in either the kidney or the ureter. The patients will be treated with Padeliporfin ImPACT in two phases, induction treatment and maintenance treatment, and will be followed up for 1-5 y...
Product Name : Padeliporfin ImPACT
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 20, 2021
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba Biotech
Details : This swiftly follows clearance of the Investigational New Drug (IND) application granted in December 2020 allowing initiation of the pivotal Phase 3 clinical trial of padeliporfin ImPACT in patients with low-grade UTUC, expected to begin enrollment in Q1...
Product Name : Padeliporfin ImPACT
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable